GB201306127D0 - Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) - Google Patents

Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9)

Info

Publication number
GB201306127D0
GB201306127D0 GBGB1306127.0A GB201306127A GB201306127D0 GB 201306127 D0 GB201306127 D0 GB 201306127D0 GB 201306127 A GB201306127 A GB 201306127A GB 201306127 D0 GB201306127 D0 GB 201306127D0
Authority
GB
United Kingdom
Prior art keywords
pcsk9
modulation
proprotein convertase
convertase subtilisin
kexin type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1306127.0A
Other versions
GB2523527A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Biotechnology Ltd
Original Assignee
London Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by London Biotechnology Ltd filed Critical London Biotechnology Ltd
Priority to GB1306127.0A priority Critical patent/GB2523527A/en
Publication of GB201306127D0 publication Critical patent/GB201306127D0/en
Publication of GB2523527A publication Critical patent/GB2523527A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
GB1306127.0A 2013-04-05 2013-04-05 Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) Withdrawn GB2523527A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1306127.0A GB2523527A (en) 2013-04-05 2013-04-05 Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1306127.0A GB2523527A (en) 2013-04-05 2013-04-05 Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9)

Publications (2)

Publication Number Publication Date
GB201306127D0 true GB201306127D0 (en) 2013-05-22
GB2523527A GB2523527A (en) 2015-09-02

Family

ID=48483354

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1306127.0A Withdrawn GB2523527A (en) 2013-04-05 2013-04-05 Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9)

Country Status (1)

Country Link
GB (1) GB2523527A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108753821A (en) * 2018-06-13 2018-11-06 黄河科技学院 A kind of PCSK9 inhibitor screening methods based on cell
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090130691A1 (en) * 2005-09-16 2009-05-21 Institut De Recherches Cliniques De Montreal Screening proteinase modulators using a chimeric protein and ski-i proprotein convertase substrates and inhibitors
CA2900402C (en) * 2006-05-08 2018-01-16 Adaerata, Limited Partnership Pcsk9 polypeptide, ligand to said polypeptide, kits and methods using said ligands
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
KR20090103894A (en) * 2006-11-27 2009-10-01 아이시스 파마수티컬즈 인코포레이티드 Methods for treating hypercholesterolemia
US20100081632A1 (en) * 2008-03-06 2010-04-01 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
AU2012214251A1 (en) * 2011-02-11 2013-09-12 Novartis Ag PCSK9 antagonists
JOP20200043A1 (en) * 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
WO2012170607A2 (en) * 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists

Also Published As

Publication number Publication date
GB2523527A (en) 2015-09-02

Similar Documents

Publication Publication Date Title
HK1243075A1 (en) Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
ZA201409210B (en) Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors
HK1219048A1 (en) Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels /kexin 9 (pcsk9) (ldl)
HK1257523A1 (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
IL266066A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
EP2968266A4 (en) Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
IL241037B (en) Compounds and uses thereof for the modulation of hemoglobin
ZA201506433B (en) Compounds and uses thereof for the modulation of hemoglobin
WO2014194117A3 (en) Novel metalloproteases
ZA201506390B (en) Compounds and uses thereof for the modulation of hemoglobin
IL241060B (en) Compounds and uses thereof for the modulation of hemoglobin
HK1257102A1 (en) Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
EP3182971A4 (en) Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
EP2968270A4 (en) Modulation of k2p channels
MX2017011879A (en) Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders.
EP3038640A4 (en) Substituted urea depsipeptide analogs as activators of the clpp endopeptidase
GB201306127D0 (en) Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9)
GB201602153D0 (en) Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9)
PT2976356T (en) Aspartic proteases
GB201305023D0 (en) Aspartic proteases
EP3341010A4 (en) Modulation of proprotein convertase subtilisin/kexin 9 expression (pcsk9) with hsp 27 and/or hsp25

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
S20A Reinstatement of application (sect. 20a/patents act 1977)

Free format text: REQUEST FOR REINSTATEMENT FILED

Effective date: 20140905

S20A Reinstatement of application (sect. 20a/patents act 1977)

Free format text: REQUEST FOR REINSTATEMENT ALLOWED

Effective date: 20141014

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)